The company has $231M in cash which is greater than its
market cap, giving the company low Price to Book and low Price to Cash valuation metrics. With
current operating costs pegged at $118M as of the end of 2016, Cempra has about two years of independent operation ahead of it.
Rumors are out there, however, that either Merck or Pfizer is interested in
buying Cempra.
On 2/27/17, ROTH Capital gave Cempra an upgrade, moving its assessment from "Neutral" to "Buy
The Morgan Stanley retainer may well be a precursor to this move. The other important sign of a likely buyout soon is that Cempra has two Phase III's in the pipeline that larger companies like Pfizer cannot replicate, and both are on track good for either FDA approval or EU approval.
Company risk in this trade seems transparent at this point:
https://seekingalpha.com/article/4058096-cempra-small-cap-biotech-may-soar-soon
--------
Short Interest - 24 % durante 2017 y - 40 % en relacion con el pico mas alto en Octubre 2016.
Grafico Diaro y Semanal alcistas en el MACD y el Chaiking Money Flow,
RSI en sobre venta en semanal
Yo dentro desde los 3.60
CEMP